Mutation load, putative and identified immunogenic neoantigens in melanoma cell lines
| Cell line code (response) | InDELs | Substitutions (total) | Non-synonymous substitutions | Tested peptides | Recognized T cell epitopes | Reference |
| MEL 04.01 (SD > 6 months) | 3 | 487 | 320 | 226 SLP | EML1(R64W) SEPT2 (R300C) CAD(R1854Q)3 | 26 |
| MEL 05.18 (CR) | 1 | 1243 | 811 | 501 SLP | RPS12(V104I) ZC3H18(G269R) TNIK(S502F) KIAA0020(P451L) ribosomal protein RPL28(S76F) |
39
39 39 26 26 |
| MEL 08.11 (PR) | 0 | 442 | 306 | 207 SLP | TP53 (L194F) | This article |
| MEL 09.10 (SD > 6 months) | 2 | 952 | 635 | 106 SSP | CLPTM1 (P485L) ETV5 (P465S) NIPAL2 (L95P) TNFRSF12A (I197N) MPDU1 (P213L) ERRFI1 (L338F) ZNF532 (S263L) | This article This article This article This article This article This article This article |
The mutation load, defined by number of insertions and deletions (InDELs) and the total number of substitutions is depicted. The number of synthetic long (SLP) or short (SSP) peptides comprise all the non-synonymous substitutions which have a detectable RNA expression (>0) in the tumor sample, excluding those that introduce a premature stop codon.
CR, complete response; PR, partial response; SD, stable disease.